Healthcare New Highs: Covidien PLC (NYSE:COV), Corcept Therapeutics Incorporated (NASDAQ:CORT), Chemed Corporation (NYSE:CHE), Accelerate Diagnostics (NASDAQ:AXDX)

Covidien PLC (NYSE:COV)’s share price hit a new 52-week high during trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $74.00 to $79.00, Analyst Ratings Net reports. The stock traded as high as $73.39 and last traded at $72.67, with a volume of 1,461,185 shares changing hands. The stock had previously closed at $71.90. Covidien plc (NYSE:COV) shares after opening at $71.97 moved to $73.39 on last trade day and at the end of the day closed at $72.50. Company price to sales ratio in past twelve months was calculated as 3.18 and price to cash ratio as 20.73. Covidien plc (NYSE:COV) showed a positive weekly performance of 2.92%.

Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, reported its financial results for the fourth quarter and full year ended December 31, 2013. Corcept Therapeutics Incorporated (NASDAQ:CORT) shares advanced 5.44% in last trading session and ended the day on $4.07. Corcept Therapeutics Incorporated (NASDAQ:CORT) return on equity ratio is recorded as -128.50% and its return on assets is -60.90%. Corcept Therapeutics Incorporated (NASDAQ:CORT) yearly performance is 103.50%.

Chemed Corporation (NYSE:CHE) CEO Kevin J. Mcnamara sold 4,000 shares of Chemed Corp. stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $84.47, for a total transaction of $337,880.00. Following the completion of the sale, the chief executive officer now directly owns 178,616 shares of the company’s stock, valued at approximately $15,087,694. The transaction was disclosed in a document filed with the SEC. Chemed Corporation (NYSE:CHE) shares moved up 0.55% in last trading session and was closed at $88.81, while trading in range of $ 88.26 – 89.61. Chemed Corporation (NYSE:CHE) year to date (YTD) performance is 16.18%.

Winning over investor confidence is often time regarded as an important part of business for drug companies, and Accelerate Diagnostics Inc (NASDAQ:AXDX) is no exception. The AXDX whose shares jumped more than 10 percent Thursday, launched an online portal that is dedicated to providing timely updates on latest and meaningful events. It seems the management team at AXDX understands that investors trade information in the capital market. Accelerate Diagnostics Inc (NASDAQ:AXDX) weekly performance is 15.19%. On last trading day company shares ended up $20.02. Accelerate Diagnostics Inc (NASDAQ:AXDX) distance from 50-day simple moving average (SMA50) is 33.77%.